scholarly article | Q13442814 |
P50 | author | Jia Wang | Q91478360 |
P2093 | author name string | Xiao-Feng Li | |
Jing Luo | |||
Chong Gao | |||
Yu-Yao Li | |||
Sheng-Xiao Zhang | |||
Meng-Ting Qiu | |||
Yu-Fei Hao | |||
P2860 | cites work | Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis | Q22299388 |
The IL-2 receptor complex: its structure, function, and target genes | Q24324541 | ||
FOXP3+ regulatory T cells in the human immune system | Q29307487 | ||
Regulatory T cells and immune tolerance | Q29616864 | ||
Immunomodulatory drugs and their application to the management of canine immune-mediated disease | Q33393823 | ||
Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases | Q33650813 | ||
Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis | Q33876826 | ||
The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity | Q33961011 | ||
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation | Q33993967 | ||
The role of interleukin-2 during homeostasis and activation of the immune system | Q34255232 | ||
IL-17 in Chronic Inflammation: From Discovery to Targeting | Q34512003 | ||
The biology of interleukin-2. | Q34585827 | ||
The Proportion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus: A Meta-Analysis | Q58766781 | ||
Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis | Q64102310 | ||
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta | Q72287439 | ||
Classification criteria for psoriatic arthritis: development of new criteria from a large international study | Q80001900 | ||
Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome | Q89219346 | ||
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial | Q93347154 | ||
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases | Q34615216 | ||
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation | Q35242438 | ||
Rheumatic diseases in China | Q36641516 | ||
Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis | Q36758692 | ||
Th17 and Th22 cells in psoriatic arthritis and psoriasis | Q37689670 | ||
Pathogenesis, classification and treatment of inflammatory myopathies | Q37862083 | ||
Regulatory T cells in nonlymphoid tissues | Q38139203 | ||
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases | Q38424758 | ||
Epigenetics of CD4+ T cells in autoimmune diseases | Q39211125 | ||
Th17 response and inflammatory autoimmune diseases | Q40110959 | ||
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy | Q40354412 | ||
Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes | Q40533256 | ||
Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up | Q44969103 | ||
Old and New Biological Therapies for Psoriasis. | Q47859049 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | psoriatic arthritis | Q511097 |
P304 | page(s) | 2040622320916014 | |
P577 | publication date | 2020-04-27 | |
P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
P1476 | title | The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2 | |
P478 | volume | 11 |
Search more.